Alteogen公司近日宣布，其已与第一三共（Daiichi Sankyo）达成独家许可协议。第一三共将获得在全球范围内使用ALT-B4 ...

China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance amid an ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...

今日，美国盖伦基金会（TheGalien Foundation）公布了素有“医药界的诺贝尔奖”之称的盖伦奖（PrixGalien USA Awards）得奖名单。该奖项表彰为改善人类健康做出的杰出科学创新，被认为是医药和生物医疗行业的最高荣誉之一。

Thank you for your patience and understanding. ENHERTU (5.4 mg/kg) is approved in more than 65 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2 positive ...

Daiichi Sankyo (TSE:4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have been awarded The Galien Foundation 2024 Prix Galien USA Award for Best Biotechnology Product for ENHERTU® (fam-trastuzumab ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

AstraZeneca and Daiichi Sankyo’s breast cancer drug Enhertu to join China’s state health insurance in 2025, enhancing ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is a brand-name solution for intravenous infusion prescribed for certain cancers. Enhertu has no known interactions with alcohol, drugs, or supplements.

Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.

The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...